Therapies targeting these components could therefore prove beneficial, for example, it has been shown that Biglycan inhibition, through a nanodevice encapsulating a siRNA delivery system, significantly impairs tumor growth of xenografted renal cell carcinoma in nude mice (Maishi et al., 2022). Here, BGN is linked to hereditary clear cell renal cell carcinoma.